- Article
- Source: Campus Sanofi
- 20 Sept 2023
Overview of the safety and efficacy data from ICARIA-MM Trial
This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.
Prescribing Information for SARCLISA®▼ (isatuximab) can be found via the Product Card at the bottom of the page.
In this video, you'll learn about
The phase 3 ICARIA-MM study of an anti-CD38 monoclonal antibody triplet regimen in relapsed and refractory multiple myeloma(RRMM) presented by Dr Ramasamy.
SARCLISA® + Pd demonstrated a 40% risk reduction in progression or death vs Pd (11.53 vs 6.47 months [absolute change 5 months]; HR 0.596, 95% CI: 0.44, 0.81; p=0.001).1
Overview of SARCLISA®
Find out more about SARCLISA® + Pd efficacy and safety data and dosing information.
Dosing and Administration Guide
Download a handy guide to SARCLISA dosing and administration information
Patient Booklet
Download SARCLISA® patient information.
Overview of SARCLISA®
Find out more about SARCLISA® + Pd efficacy and safety data and dosing information.
Dosing and Administration Guide
Download a handy guide to SARCLISA dosing and administration information
Patient Booklet
Download SARCLISA® patient information.
Relapsed Refractory Multiple Myeloma Product
MAT-XU-2202578 (v4.0)
Date of preparation: June 2024
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
References
-
Attal M, et al. Lancet. 2019;394:2096–107.
MAT-XU-2202565 (v3.0) Date of Preparation: June 2024